Oxytocin in schizophrenia: a review of evidence for its therapeutic effects
1University of California, San Diego Medical Center Department of Psychiatry.
Background:
The suggestion that the neurohormone oxytocin may have clinical application in the treatment of schizophrenia was first published in 1972. Since then, a considerable body of research on a variety of fronts--including several recent double-blind treatment trials-has buttressed these early reports, providing support for the assertion that the oxytocin system is a promising and novel therapeutic target for this devastating malady. Herein, we review the diverse, convergent lines of evidence supporting the therapeutic potential of oxytocin in psychotic illness.
Methods:
We performed a systematic review of preclinical and clinical literature pertaining to oxytocin's role in schizophrenia.
Results:
Multiple lines of evidence converge to support the antipsychotic potential of oxytocin. These include several animal models of schizophrenia, pharmacological studies examining the impact of antipsychotics on the oxytocin system, human trials in patients examining aspects of the oxytocin system, and several double-blind, placebo-controlled clinical treatment trials.
Conclusions:
There exists considerable, convergent evidence that oxytocin has potential as a novel antipsychotic with a unique mechanism of action. Auspiciously, based on the few chronic trials to date, its safety profile and tolerability appear very good. That said, several critical clinical questions await investigation before widespread use is clinically warranted.
Insights
Oxytocin shows promise as a novel antipsychotic for schizophrenia treatment. Research indicates a good safety profile, but further clinical questions require investigation before widespread use.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- The neurohormone oxytocin was first suggested for schizophrenia treatment in 1972.
- Recent research, including double-blind trials, supports oxytocin's therapeutic potential for psychotic illness.
Purpose of the Study:
- To review evidence for oxytocin's therapeutic potential in schizophrenia.
- To consolidate findings from preclinical and clinical studies.
Main Methods:
- Systematic review of preclinical and clinical literature.
- Analysis of animal models, pharmacological studies, and human trials.
Main Results:
- Convergent evidence supports oxytocin's antipsychotic potential.
- Studies include animal models, drug impact assessments, and placebo-controlled trials.
Conclusions:
- Oxytocin shows potential as a novel antipsychotic with a unique mechanism.
- Current trials suggest good safety and tolerability.
- Further clinical investigation is needed before widespread application.
Related Concept Videos
01:31Neurotransmitters
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:29Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:29Psychological and Sociocultural Causes of Schizophrenia
01:26Psychosis: Goals of Pharmacotherapy